Lethargic Depression Study
Lethargic Depression Study
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy,
 pleasure and interests.
A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of
 flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for
 eight weeks for the treatment of adult outpatients with major depressive disorder including
 symptoms of decreased energy, pleasure, and interest
Inclusion criteria:

 -  Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2
 years.

 -  Generally in good health.

 -  Subject must read and write at a level sufficient to provide written informed consent.

 Exclusion criteria:

 -  Current or past history of seizure disorder.

 -  Subject has a primary diagnosis or received treatment for panic disorder, obsessive
 compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress
 disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.

 -  Currently using illicit drugs or other psychotropic drugs.

 -  Patient poses a current suicidal risk or has attempted suicide in the past 6 months.